Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis
Canadian Medical Association Journal2020Vol. 192(27), pp. E756–E767
Citations Over TimeTop 10% of 2020 papers
Zhikang Ye, Ying Wang, Luis Enrique Colunga‐Lozano, Manya Prasad, Wimonchat Tangamornsuksan, Bram Rochwerg, Liang Yao, Shahrzad Motaghi, Rachel Couban, Maryam Ghadimi, Małgorzata M Bała, Huda Gomaa, Fang Fang, Yingqi Xiao, Gordon Guyatt
Abstract
Corticosteroids may reduce mortality for patients with COVID-19 and ARDS. For patients with severe COVID-19 but without ARDS, evidence regarding benefit from different bodies of evidence is inconsistent and of very low quality.
Related Papers
- → COVID-19, SARS and MERS: are they closely related?(2020)1,138 cited
- → A comparative overview of COVID-19, MERS and SARS: Review article(2020)140 cited
- → Past and current Coronavirus outbreaks; Focusing on Coronavirus Disease 2019 in comparison with Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome(2020)4 cited
- An Overview on the Traditional Chinese Medicine Treatment Guidelines for Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)(2015)
- Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)(2020)